Chemistry:Etamicastat
From HandWiki
Etamicastat (INN; developmental code name BIA 5-453) is a peripherally selective dopamine β-hydroxylase (DBH) inhibitor which was under development for the treatment of hypertension (high blood pressure) and heart failure but was never marketed.[1][2] The peripheral selectivity of etamicastat is in contrast to the earlier DBH inhibitor nepicastat, which is centrally active and produced associated side effects.[2] Etamicastat was found to reduce blood pressure but not affect heart rate in clinical trials.[2] The development of etamicastat was discontinued by August 2016.[1]
See also
- Nepicastat
- Zamicastat
References
- ↑ 1.0 1.1 "Etamicastat". 27 December 2019. https://adisinsight.springer.com/drugs/800034724.
- ↑ 2.0 2.1 2.2 "Dopamine β hydroxylase as a potential drug target to combat hypertension". Expert Opin Investig Drugs 29 (9): 1043–1057. September 2020. doi:10.1080/13543784.2020.1795830. PMID 32658551.
 |  |
